A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
5-O-phosphono-alpha-D-ribofuranosyl diphosphate
Racepinephrine
The risk or severity of hypokalemia can be increased when Prednisolone acetate is combined with Racepinephrine.
5-O-phosphono-alpha-D-ribofuranosyl diphosphate
Doxofylline
The risk or severity of hypokalemia can be increased when Prednisolone acetate is combined with Doxofylline.
5-O-phosphono-alpha-D-ribofuranosyl diphosphate
Vilanterol
The risk or severity of hypokalemia can be increased when Prednisolone acetate is combined with Vilanterol.
5-O-phosphono-alpha-D-ribofuranosyl diphosphate
Olodaterol
The risk or severity of hypokalemia can be increased when Prednisolone acetate is combined with Olodaterol.
5-O-phosphono-alpha-D-ribofuranosyl diphosphate
Hexoprenaline
The risk or severity of hypokalemia can be increased when Prednisolone acetate is combined with Hexoprenaline.
5-O-phosphono-alpha-D-ribofuranosyl diphosphate
Protokylol
The risk or severity of hypokalemia can be increased when Prednisolone acetate is combined with Protokylol.
5-O-phosphono-alpha-D-ribofuranosyl diphosphate
Celiprolol
The risk or severity of hypokalemia can be increased when Prednisolone acetate is combined with Celiprolol.
5-O-phosphono-alpha-D-ribofuranosyl diphosphate
Hyaluronidase
The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Prednisolone acetate.
5-O-phosphono-alpha-D-ribofuranosyl diphosphate
Hyaluronidase (human recombinant)
The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Prednisolone acetate.
5-O-phosphono-alpha-D-ribofuranosyl diphosphate
Corticorelin ovine triflutate
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Prednisolone acetate.
5-O-phosphono-alpha-D-ribofuranosyl diphosphate
Aripiprazole lauroxil
The metabolism of Aripiprazole lauroxil can be increased when combined with Prednisolone acetate.
Methyl nonanoate
Satralizumab
The serum concentration of Elexacaftor can be decreased when it is combined with Satralizumab.
Methyl nonanoate
Abametapir
The serum concentration of Elexacaftor can be increased when it is combined with Abametapir.
Methyl nonanoate
Cenobamate
The serum concentration of Elexacaftor can be decreased when it is combined with Cenobamate.
Methyl nonanoate
Berotralstat
The serum concentration of Elexacaftor can be increased when it is combined with Berotralstat.
Methyl nonanoate
Fosnetupitant
The serum concentration of Elexacaftor can be increased when it is combined with Fosnetupitant.
Methyl nonanoate
Benidipine
The serum concentration of Elexacaftor can be increased when it is combined with Benidipine.
Methyl nonanoate
Barnidipine
The serum concentration of Elexacaftor can be increased when it is combined with Barnidipine.
Methyl nonanoate
Indalpine
The serum concentration of Elexacaftor can be increased when it is combined with Indalpine.
Methyl nonanoate
Luliconazole
The serum concentration of Elexacaftor can be increased when it is combined with Luliconazole.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3